Leukemia - Table of Contents alert Volume 26 Issue 4

TABLE OF CONTENTS Volume 26, Issue 4 (April 2012) In this issue Reviews Original Articles Letters to the Editor Also new AOP Advertisement BD Reagents for Blood Cell Disorders Part of the building blocks to support patient care for blood cell disorders, BD Biosciences reagents provide a full spectrum of color choices, allowing you to analyze multiple parameters simultaneously and access a whole new world of information and insight. Welcome to a more colorful worldSM. bdbiosciences.com/go/color Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement 90 page eBook --- download now for free! Published in January 2012 Key Advances in Medicine summarizes the key clinical studies published in 2011 and highlights the trends to watch for in 2012. The perfect resource for busy medical students, physicians, and clinical researchers who want to catch up with the medical literature from 2011. Don't miss out!   Reviews Top Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera H Reikvam and R V Tiu Leukemia 2012 26: 563-571; advance online publication, November 11, 2011; 10.1038/leu.2011.314 Abstract | Full Text NKL homeobox genes in leukemia I Homminga, R Pieters and J P P Meijerink Leukemia 2012 26: 572-581; advance online publication, November 18, 2011; 10.1038/leu.2011.330 Abstract | Full Text Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review A Kumar, A R Mhaskar, T Reljic, R S Mhaskar, M A Kharfan-Dabaja, C Anasetti, M Mohty and B Djulbegovic Leukemia 2012 26: 582-588; advance online publication, December 20, 2011; 10.1038/leu.2011.349 Abstract | Full Text Bisphosphonates as antimyeloma drugs N D Modi and S Lentzsch Leukemia 2012 26: 589-594; advance online publication, October 18, 2011; 10.1038/leu.2011.282 Abstract | Full Text Management of treatment-emergent peripheral neuropathy in multiple myeloma P G Richardson, M Delforge, M Beksac, P Wen, J L Jongen, O Sezer, E Terpos, N Munshi, A Palumbo, S V Rajkumar, J L Harousseau, P Moreau, H Avet-Loiseau, J H Lee, M Cavo, G Merlini, P Voorhees, W J Chng, A Mazumder, S Usmani, H Einsele, R Comenzo, R Orlowski, D Vesole, J J Lahuerta, R Niesvizky, D Siegel, M-V Mateos, M Dimopoulos, S Lonial, S Jagannath, J Bladé, J San Miguel, G Morgan, K C Anderson, B G M Durie and P Sonneveld on behalf of the International Myeloma Working Group Leukemia 2012 26: 595-608; advance online publication, December 23, 2011; 10.1038/leu.2011.346 Abstract | Full Text Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites A J Greenberg, C M Vachon and S V Rajkumar Leukemia 2012 26: 609-614; advance online publication, December 23, 2011; 10.1038/leu.2011.368 Abstract | Full Text Original Articles Top MOLECULAR TARGETS FOR THERAPY Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I T Bujnicki, C Wilczek, C Schomburg, F Feldmann, P Schlenke, C Müller-Tidow, T J Schmidt and K-H Klempnauer Leukemia 2012 26: 615-622; advance online publication, October 11, 2011; 10.1038/leu.2011.275 Abstract | Full Text ACUTE LEUKEMIAS Targeting survivin and p53 in pediatric acute lymphoblastic leukemia J W Tyner, A M Jemal, M Thayer, B J Druker and B H Chang Leukemia 2012 26: 623-632; advance online publication, September 30, 2011; 10.1038/leu.2011.249 Abstract | Full Text Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity L Grkovic, K Baird, S M Steinberg, K M Williams, D Pulanic, E W Cowen, S A Mitchell, F T Hakim, K J Martires, D N Avila, T N Taylor, R B Salit, S D Rowley, D Zhang, D H Fowler, M R Bishop, R E Gress and S Z Pavletic Leukemia 2012 26: 633-643; advance online publication, October 18, 2011; 10.1038/leu.2011.254 Abstract | Full Text c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells T Waldron, M De Dominici, A R Soliera, A Audia, I Iacobucci, A Lonetti, G Martinelli, Y Zhang, R Martinez, T Hyslop, T P Bender and B Calabretta Leukemia 2012 26: 644-653; advance online publication, September 30, 2011; 10.1038/leu.2011.264 Abstract | Full Text Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report U Creutzig, M Zimmermann, J-P Bourquin, M N Dworzak, B Kremens, T Lehrnbecher, C von Neuhoff, A Sander, A von Stackelberg, I Schmid, J Starý, D Steinbach, J Vormoor and D Reinhardt Leukemia 2012 26: 654-661; advance online publication, October 4, 2011; 10.1038/leu.2011.267 Abstract | Full Text Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1 H Chaib, A Nebbioso, T Prebet, R Castellano, S Garbit, A Restouin, N Vey, L Altucci and Y Collette Leukemia 2012 26: 662-674; advance online publication, October 7, 2011; 10.1038/leu.2011.271 Abstract | Full Text High concordance of subtypes of childhood acute lymphoblastic leukemia within families: lessons from sibships with multiple cases of leukemia K Schmiegelow, U Lausten Thomsen, A Baruchel, C E Pacheco, Rob Pieters, M S Pombo-de-Oliveira, E W Andersen, K Rostgaard, H Hjalgrim and C-H Pui Leukemia 2012 26: 675-681; advance online publication, October 18, 2011; 10.1038/leu.2011.274 Abstract | Full Text Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia D J P M Stumpel, P Schneider, L Seslija, H Osaki, O Williams, R Pieters and R W Stam Leukemia 2012 26: 682-692; advance online publication, October 21, 2011; 10.1038/leu.2011.278 Abstract | Full Text MYELODYSPLASIAS IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes A Pardanani, C Finke, T L Lasho, A Al-Kali, K H Begna, C A Hanson and A Tefferi Leukemia 2012 26: 693-699; advance online publication, September 13, 2011; 10.1038/leu.2011.251 Abstract | Full Text Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia R T Calado, J N Cooper, H M Padilla-Nash, E M Sloand, C O Wu, P Scheinberg, T Ried and N S Young Leukemia 2012 26: 700-707; advance online publication, October 18, 2011; 10.1038/leu.2011.272 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms A Deshpande, M M Reddy, G O M Schade, A Ray, T K Chowdary, J D Griffin and M Sattler Leukemia 2012 26: 708-715; advance online publication, September 16, 2011; 10.1038/leu.2011.255 Abstract | Full Text Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria G Finazzi, A Carobbio, J Thiele, F Passamonti, E Rumi, M Ruggeri, F Rodeghiero, M L Randi, I Bertozzi, A M Vannucchi, E Antonioli, H Gisslinger, V Buxhofer-Ausch, N Gangat, A Rambaldi, A Tefferi and T Barbui Leukemia 2012 26: 716-719; advance online publication, September 16, 2011; 10.1038/leu.2011.258 Abstract | Full Text EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L G Wernig, M G Kharas, A Mullally, D S Leeman, R Okabe, T George, D O Clary and D G Gilliland Leukemia 2012 26: 720-727; advance online publication, October 18, 2011; 10.1038/leu.2011.261 Abstract | Full Text Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders T Bochtler, M Kirsch, B Maier, J Bachmann, U Klingmüller, S Anderhub, A D Ho and A Krämer Leukemia 2012 26: 728-735; advance online publication, October 21, 2011; 10.1038/leu.2011.283 Abstract | Full Text STEM CELLS The bone marrow-expressed antimicrobial cationic peptide LL-37 enhances the responsiveness of hematopoietic stem progenitor cells to an SDF-1 gradient and accelerates their engraftment after transplantation W Wu, C H Kim, R Liu, M Kucia, W Marlicz, N Greco, J Ratajczak, M J Laughlin and M Z Ratajczak Leukemia 2012 26: 736-745; advance online publication, September 20, 2011; 10.1038/leu.2011.252 Abstract | Full Text IMMUNOLOGY Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study Z Kuzmina, S Eder, A Böhm, E Pernicka, L Vormittag, P Kalhs, V Petkov, G Stary, J Nepp, R Knobler, U Just, K Krenn, N Worel and H T Greinix Leukemia 2012 26: 746-756; advance online publication, September 16, 2011; 10.1038/leu.2011.257 Abstract | Full Text SENSITIVITY AND RESISTANCE TO THERAPY Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells N E Franke, D Niewerth, Y G Assaraf, J van Meerloo, K Vojtekova, C H van Zantwijk, S Zweegman, E T Chan, C J Kirk, D P Geerke, A D Schimmer, G J L Kaspers, G Jansen and J Cloos Leukemia 2012 26: 757-768; advance online publication, September 23, 2011; 10.1038/leu.2011.256 Abstract | Full Text ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-α and cAMP/PKA pathways M Lv, X Zhang, H Jia, D Li, B Zhang, H Zhang, M Hong, T Jiang, Q Jiang, J Lu, X Huang and B Huang Leukemia 2012 26: 769-777; advance online publication, October 7, 2011; 10.1038/leu.2011.273 Abstract | Full Text APOPTOSIS MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex M Konopleva, M Milella, P Ruvolo, J C Watts, M R Ricciardi, B Korchin, T McQueen, W Bornmann, T Tsao, P Bergamo, D H Mak, W Chen, J McCubrey, A Tafuri and M Andreeff Leukemia 2012 26: 778-787; advance online publication, November 8, 2011; 10.1038/leu.2011.287 Abstract | Full Text Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors D H Mak, R-Y Wang, W D Schober, M Konopleva, J Cortes, H Kantarjian, M Andreeff and B Z Carter Leukemia 2012 26: 788-794; advance online publication, October 28, 2011; 10.1038/leu.2011.285 Abstract | Full Text LYMPHOMA Involvement of the Syk–mTOR pathway in follicular lymphoma cell invasion and angiogenesis S Fruchon, S Kheirallah, T Al Saati, L Ysebaert, C Laurent, L Leseux, J J Fournié, G Laurent and C Bezombes Leukemia 2012 26: 795-805; advance online publication, September 16, 2011; 10.1038/leu.2011.248 Abstract | Full Text Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed–Sternberg cells R Schwarzer, B Dörken and F Jundt Leukemia 2012 26: 806-813; advance online publication, September 27, 2011; 10.1038/leu.2011.265 Abstract | Full Text Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation A Dagklis, M Ponzoni, S Govi, M G Cangi, E Pasini, F Charlotte, A Vino, C Doglioni, F Davì, I S Lossos, I Ntountas, T Papadaki, R Dolcetti, A J M Ferreri, K Stamatopoulos and P Ghia Leukemia 2012 26: 814-821; advance online publication, October 25, 2011; 10.1038/leu.2011.276 Abstract | Full Text Letters to the Editor Top Interest of the association azacitidine–lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype E Scherman, S Malak, C Perot, N C Gorin, M T Rubio and F Isnard Leukemia 2012 26: 822-824; advance online publication, October 14, 2011; 10.1038/leu.2011.284 Full Text Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib G Georgiou, A Efthymiou, I Vardounioti, G Boutsikas, M K Angelopoulou, T P Vassilakopoulos, M-C Kyrtsonis, E Plata, P Tofas, A Bitsani, V Bartzi, I Pessach, M Dimou and P Panayiotidis Leukemia 2012 26: 824-826; advance online publication, October 11, 2011; 10.1038/leu.2011.280 Full Text Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage B Britt-Compton, T T Lin, G Ahmed, V Weston, R E Jones, C Fegan, D G Oscier, T Stankovic, C Pepper and D M Baird Leukemia 2012 26: 826-830; advance online publication, October 11, 2011; 10.1038/leu.2011.281 Full Text Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity C Kellner, D Hallack, P Glorius, M Staudinger, S Mohseni Nodehi, M de Weers, J G J van de Winkel, P W H I Parren, M Stauch, T Valerius, R Repp, A Humpe, M Gramatzki and M Peipp Leukemia 2012 26: 830-834; advance online publication, October 18, 2011; 10.1038/leu.2011.288 Full Text Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases C Haferlach, V Grossmann, A Kohlmann, S Schindela, W Kern, S Schnittger and T Haferlach Leukemia 2012 26: 834-839; advance online publication, October 21, 2011; 10.1038/leu.2011.296 Full Text Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy S Sinha, M Lacy, J Mikhael, S Hayman, F Buadi, K Detweiler-Short, A Dispenzieri, M Gertz, D Dingli, S V Rajkumar and S K Kumar Leukemia 2012 26: 839-841; advance online publication, October 11, 2011; 10.1038/leu.2011.279 Full Text Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia D M Kofler, B B Gawlik, T Elter, A Gianella-Borradori, C-M Wendtner and M Hallek Leukemia 2012 26: 841-844; advance online publication, October 7, 2011; 10.1038/leu.2011.286 Full Text Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma O Landgren, W Ma, R A Kyle, S V Rajkumar, N Korde and M Albitar Leukemia 2012 26: 844-845; advance online publication, September 16, 2011; 10.1038/leu.2011.262 Full Text Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation K van der Weide, P M Korthuis, F Kuipers, E G E de Vries and E Vellenga Leukemia 2012 26: 845-848; advance online publication, September 20, 2011; 10.1038/leu.2011.259 Full Text Downregulation of MEIS1 impairs long-term expansion of CD34+ NPM1-mutated acute myeloid leukemia cells C M Woolthuis, L Han, R N Verkaik-Schakel, D van Gosliga, P M Kluin, E Vellenga, J J Schuringa and G Huls Leukemia 2012 26: 848-853; advance online publication, October 11, 2011; 10.1038/leu.2011.277 Full Text Effect of nucleophosmin1 haploinsufficiency on hematopoietic stem cells A Raval, B Kusler, W W Pang, I L Weissman, B S Mitchell and C Y Park Leukemia 2012 26: 853-855; advance online publication, October 7, 2011; 10.1038/leu.2011.270 Full Text Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide A A N Giagounidis, A Kulasekararaj, U Germing, R Radkowski, S Haase, P Petersen, G Göhring, G Büsche, C Aul, G J Mufti and U Platzbecker Leukemia 2012 26: 855-858; advance online publication, September 30, 2011; 10.1038/leu.2011.268 Full Text Frequency of leukemic initiating cells does not depend on the xenotransplantation model used J Vargaftig, D C Taussig, E Griessinger, F Anjos-Afonso, T A Lister, J Cavenagh, H Oakervee, J Gribben and D Bonnet Leukemia 2012 26: 858-860; advance online publication, September 16, 2011; 10.1038/leu.2011.250 Full Text Advertisement Ensure your access If you are unable to access the articles in this Table of Contents e-alert, your library may not subscribe to this journal. Our online recommendation form is a simple way to make your librarian aware that this journal is valuable to your research. Recommend now.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.